Advertisement
open access | | logout
Medical Conferences

Medical Conferences

  • Conference Reports
  • Conference Proceedings
  • Specialties
    • Cardiology
    • Dermatology
    • Endocrinology
    • Gastroenterology
    • Haematology
    • Nephrology
    • Neurology
    • Oncology
    • Psychiatry
    • Pulmonology
    • Rheumatology
    • Urology
  • Multimedia
    • Podcast channel
    • Video channel
  • About
    • 2025 Medicom Conference Planning
    • About Conference Proceedings
    • Webinar
Home > Oncology > ASCO 2024

ASCO 2024


American Society of Clinical Oncology
31 May–04 June 2024
Chicago, IL, USA
  • Table of Contents
  • Colophon

Table of Contents



Featured articles

Letter from the Editor

Editor
Dr Stefan Rauh, Centre Hospitalier Emile Mayrisch, Luxembourg

Meet the Trialist: Prof. Giuseppe Curigliano on DESTINY-Breast06

Expert
Prof. Giuseppe Curigliano, University of Milan, Italy

Gastrointestinal: Colorectal Cancer

No survival benefit of tumour debulking for patients with multi-organ metastatic CRC

Presented By
Dr Elske Gootjes, Radboudumc, the Netherlands

Thermal ablation of small-size colorectal liver metastases is non-inferior to resection

Presented By
Prof. Martijn Meijerink, Amsterdam UMC, the Netherlands

Benefit of first-line nivolumab/ipilimumab in MSI-H/dMMR metastatic CRC

Presented By
Prof. Heinz-Josef Lenz, University of Southern California Norris Comprehensive Cancer Center, CA, USA

Neoadjuvant checkpoint blockade in MSI-H/dMMR CRC

CodeBreaK 300: Promising survival trends in KRAS G12C-mutated mCRC

Presented By
Prof. Marwan Fakih, City of Hope Comprehensive Cancer Center, CA, USA

Gastrointestinal: Upper GI Cancer

FLOT outperforms CROSS in resectable oesophageal cancer

Presented By
Prof. Jens Höppner, University of Bielefeld, Germany

Nivolumab/ipilimumab combination outperforms TKIs in unresectable HCC

Presented By
Dr Peter Galle, Universitätsmedizin Mainz, Germany

No advantage of neoadjuvant radiochemotherapy over neoadjuvant chemotherapy in borderline resectable pancreatic cancer

Presented By
Dr Masafumi Ikeda, National Cancer Center Hospital East, Japan

Breast Cancer

Benefit of abemaciclib plus fulvestrant after progression on a CDK4/6 inhibitor

Presented By
Prof. Kevin Kalinsky, Emory School of Medicine, GA, USA

ctDNA is prognostic of worse outcomes for CDK4/6 therapy

Presented By
Prof. Sherene Loi, Peter MacCallum Cancer Centre, Australia

Adjuvant avelumab significantly improves survival in early TNBC

Presented By
Prof. Pierfranco Conte, University of Padova, Italy

High pCR rate after neoadjuvant Dato-DXd plus durvalumab therapy

Presented By
Dr Jane Meisel, Emory School of Medicine, GA, USA & Dr Rebecca Shatsky, University of California San Diego, CA, USA

Lung Cancer

Osimertinib significantly improves PFS in patients with unresectable stage III EGFR-mutated NSCLC

Presented By
Prof. Suresh Ramalingam, Emory School of Medicine, GA, USA

First-line lorlatinib provides unprecedented improvement for patients with advanced ALK-positive NSCLC

Presented By
Prof. Benjamin Solomon, Peter MacCallum Cancer Centre, Australia

Comparable benefit of video- and in-person-delivered palliative care

Presented By
Dr Joseph Greer, Harvard Medical School, MA, USA

Consolidation with durvalumab improves survival in LS-SCLC

Presented By
Dr David Spigel, Sarah Cannon Research Institute, TN, USA

Subcutaneous amivantamab non-inferior and more convenient than intravenous amivantamab

Presented By
Dr Natasha Leighl, Princess Margaret Cancer Centre, Canada

Melanoma

Highly significant event-free survival benefit with neoadjuvant nivolumab/ipilimumab in stage III melanoma

Presented By
Prof. Christian Blank, Antoni van Leeuwenhoek, the Netherlands

Neoadjuvant intralesional daromun improves relapse-free survival in stage III melanoma

Presented By
Prof. Axel Hauschild, Universitätsklinikum Schleswig-Holstein, Germany

Intratumoural tilsotolimod shows no benefit for advanced refractory melanoma

Presented By
Prof. Caroline Robert, Gustave Roussy, France

Genitourinary Cancer

Immune-enhancing nutrition does not affect complication rate of radical cystectomy

Presented By
Prof. Jill Hamilton-Reeves, University of Kansas Medical Center, KS, USA

Biomarkers for treatment of renal cell carcinoma

ctDNA changes as biomarker for pembrolizumab response in advanced urothelial carcinoma

Presented By
Prof. Thomas Powles, Barts Cancer Institute, UK

Highest efficacy of nivolumab/chemotherapy in lymph-node-only metastatic urothelial carcinoma

Presented By
Prof. Matthew Galsky, Tisch Cancer Institute, NY, USA

Genitourinary: Prostate Cancer

Metformin does not prevent progression of low-risk prostate cancer

Presented By
Dr Anthony Joshua, Princess Margaret Cancer Centre, Canada

Baseline ctDNA has both prognostic and predictive value in mCRPC

Presented By
Prof. Johann de Bono, Royal Marsden Hospital, UK

Oxybutynin significantly decreases frequency and severity of hot flashes in men on ADT

Presented By
Dr Brad Stish, Mayo Clinic, MN, USA

Gynaecological Cancer

Batiraxcept shows promise in high AXL-expressing, platinum-resistant ovarian cancer

Presented By
Dr Katherine Fuh, University of California San Francisco, CA, USA

No lymphadenectomy for advanced ovarian cancer without suspicious nodes

Presented By
Prof. Jean-Marc Classe, Nantes Université, France

SIENDO: Efficacy benefit of selinexor in TP53 wildtype endometrial cancer

Presented By
Dr Vicky Makker, Memorial Sloan Kettering Cancer Center, NY, USA

Novel regimen for HR-positive endometrial cancer on the way?

Presented By
Dr Angela Green, Memorial Sloan Kettering Cancer Center, NY, USA
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com